Name
Abstract | ||
|---|---|---|
Molecular imaging, including fluorescence imaging (FMI), bioluminescence imaging (BLI), positron emission tomography (PET), single-photon emission-computed tomography (SPECT), and computed tomography (CT), has a pivotal role in the process of tumor and relevant drug research. CT, especially Micro-CT, can provide the anatomic information for a region of interest (ROI); PET and SPECT can provide functional information for the ROI. BLI and FMI can provide optical information for an ROI. Tumor angiogenesis and relevant drug development is a lengthy, high-risk, and costly process, in which a novel drug needs about 10-15 years of testing to obtain Federal Drug Association (FDA) approval. Molecular imaging can enhance the development process by understanding the tumor mechanisms and drug activity. In this paper, we focus on tumor angiogenesis, and we review the characteristics of molecular imaging modalities and their applications in tumor angiogenesis and relevant drug research. |
Year | DOI | Venue |
|---|---|---|
2011 | 10.1155/2011/370701 | Int. J. Biomedical Imaging |
Keywords | Field | DocType |
bioluminescence imaging,drug activity,tumor mechanism,relevant drug research,tumor angiogenesis,molecular imaging,novel drug,molecular imaging modality,fluorescence imaging,relevant drug development,biomedical research,biomedical,bioinformatics,imaging | Molecular imaging,Bioluminescence imaging,Fluorescence-lifetime imaging microscopy,Drug development,Tomography,Positron emission tomography,Angiogenesis,Region of interest,Medicine,Pathology | Journal |
Volume | ISSN | Citations |
2011 | 1687-4196 | 0 |
PageRank | References | Authors |
0.34 | 1 | 4 |
Name | Order | Citations | PageRank |
|---|---|---|---|
| Xibo Ma | 1 | 7 | 2.70 |
| Jie Tian | 2 | 1475 | 159.24 |
| Xin Yang | 3 | 249 | 31.55 |
| Chenghu Qin | 4 | 21 | 7.30 |